Mesna
From Wikipedia, the free encyclopedia
 |
|
|
Mesna
|
|
| Systematic (IUPAC) name | |
| sodium 2-sulfanylethanesulfonate | |
| Identifiers | |
| CAS number | |
| ATC code | R05 V03AF01 |
| PubChem | |
| Chemical data | |
| Formula | C2H5NaO3S2 |
| Mol. mass | 164.181 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 45–79% (Oral) |
| Metabolism | Oxidised in circulation |
| Half life | 0.36–8.3 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status |
S4 (Au), POM (UK), ℞-only (U.S.) |
| Routes | Oral, intravenous |
Mesna (INN) (IPA: [ˈmɛznə]) is an adjuvant used in cancer chemotherapy involving cyclophosphamide and ifosfamide. It is currently marketed by Baxter as Uromitexan® and Mesnex®.
Mesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites such as acrolein. Mesna assists to neutralise these metabolites by binding through its sulfhydryl-moieties, and also increases urinary excretion of cysteine.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
